AI assistant
AstraZeneca PLC — Remuneration Information 2019
Mar 12, 2019
5229_dirs_2019-03-12_25317eac-be55-4db3-a50d-b1201066d615.html
Remuneration Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 5981S
AstraZeneca PLC
12 March 2019
12 March 2019 12:00 GMT
TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES
AstraZeneca PLC (the Company) announces that, on 8 March 2019, certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) were granted awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) under the terms of the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP), as detailed in the table below.
| PDMR | Ordinary Shares granted under the AZDBP | Ordinary Shares granted under the AZPSP | Award price per Ordinary Share |
| Pascal Soriot | 9,849 | 102,475 | £62.87 |
| Marc Dunoyer | 4,874 | 48,690 | £62.87 |
The AZDBP award represents the portion of each PDMR's annual bonus for 2018 that they are required to defer into shares. The Ordinary Shares granted under the AZDBP are subject to a three-year holding period and are due to vest on the third anniversary of grant.
The AZPSP award is subject to a combination of performance measures focused on scientific, commercial and financial performance assessed over a three-year performance period (1 January 2019 to 31 December 2021). The Ordinary Shares granted under the AZPSP are subject to a two-year holding period following the performance period, and are due to vest on the fifth anniversary of grant.
Details of the performance measures attached to the AZPSP award can be found in the Directors' Remuneration Report within the AstraZeneca Annual Report and Form 20-F Information 2018, which is available on the Company's website at www.astrazeneca.com/annualreport2018.
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Pascal Soriot
2
Reason for the notification
a)
Position/status
Chief Executive Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
AstraZeneca PLC
b)
LEI
PY6ZZQWO2IZFZC3IOL08
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
b)
Nature of the transaction
Grants of share awards under the AstraZeneca Performance Share Plan and the AstraZeneca Deferred Bonus Plan
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £62.87 | 112,324 |
d)
Aggregated information
- Aggregated volume
- Price
Not applicable - single transaction
e)
Date of the transaction
8 March 2019
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Marc Dunoyer
2
Reason for the notification
a)
Position/status
Chief Financial Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
AstraZeneca PLC
b)
LEI
PY6ZZQWO2IZFZC3IOL08
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
b)
Nature of the transaction
Grants of share awards under the AstraZeneca Performance Share Plan and the AstraZeneca Deferred Bonus Plan
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £62.87 | 53,564 |
d)
Aggregated information
- Aggregated volume
- Price
Not applicable - single transaction
e)
Date of the transaction
8 March 2019
f)
Place of the transaction
Outside a trading venue
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
| Media Relations | ||
| Gonzalo Viña | UK/Global | +44 203 749 5916 |
| Rob Skelding | UK/Global | +44 203 749 5821 |
| Matt Kent | UK/Global | +44 203 749 5906 |
| Jennifer Hursit | UK/Global | +44 203 749 5762 |
| Christina Malmberg Hägerstrand | Sweden | +46 8 552 53 106 |
| Michele Meixell | US | +1 302 885 2677 |
| Investor Relations | ||
| Thomas Kudsk Larsen | +44 203 749 5712 | |
| Henry Wheeler | Oncology | +44 203 749 5797 |
| Christer Gruvris | BioPharma - Cardiovascular; Metabolism | +44 203 749 5711 |
| Nick Stone | BioPharma - Respiratory; Renal | +44 203 749 5716 |
| Josie Afolabi | Other | +44 203 749 5631 |
| Craig Marks | Finance; Fixed Income | +44 7881 615 764 |
| Jennifer Kretzmann | Retail Investors; Corporate Access | +44 203 749 5824 |
| US toll-free | +1 866 381 72 77 |
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
DSHUUARRKNAOAAR